Nelarabine

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Nelarabine
Nelarabine structure.svg
Nelarabine ball-and-stick.png
Clinical data
AHFS/Drugs.com Monograph
License data
Pregnancy
category
  • US: D (Evidence of risk)
Routes of
administration
Intravenous
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability n/a
Protein binding <25%
Metabolism By adenosine deaminase, to 9-β-D-arabinofuranosylguanine
Biological half-life 30 minutes (nelarabine)
3 hours (ara-G)
Excretion Renal
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
ECHA InfoCard 100.170.768
Chemical and physical data
Formula C11H15N5O5
Molar mass 297.268 g/mol
3D model (Jmol)
 NYesY (what is this?)  (verify)

Nelarabine is a chemotherapy drug used in T-cell acute lymphoblastic leukemia. It was previously known as 506U78.

Nelarabine is arabinosylguanine nucleotide triphosphate (araGTP), a type of purine nucleoside analog, which causes inhibition of DNA synthesis and cytotoxicity.[1] Pre-clinical studies suggest that T-cells are particularly sensitive to nelarabine. In October 2005, it was approved by the FDA for acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma that has not responded to or has relapsed following treatment with at least two chemotherapy regimens.[2] It was later approved in the European Union in October 2005. Complete responses have been achieved with this medication.

It is marketed in the US as Arranon and as Atriance in the EU by Novartis.[3]

References[edit]

  1. ^ "Nelarabine". Guide to Pharmacology. IUPHAR/BPS. Retrieved 21 August 2015. 
  2. ^ Cohen, M. H.; Johnson, J. R.; Justice, R; Pazdur, R (2008). "FDA drug approval summary: Nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia/lymphoma". The Oncologist. 13 (6): 709–14. doi:10.1634/theoncologist.2006-0017. PMID 18586926. 
  3. ^ http://www.novartisoncology.com/products/atriance.jsp